A joint frailty-copula model between tumour progression and death for meta-analysis

Abstract

Dependent censoring often arises in biomedical studies when time to tumour progression (e.g., relapse of cancer) is censored by an informative terminal event (e.g., death). For meta-analysis combining existing studies, a joint survival model between tumour progression and death has been considered under semicompeting risks, which induces dependence through the study-specific frailty. Our paper here utilizes copulas to generalize the joint frailty model by introducing additional source of dependence arising from intra-subject association between tumour progression and death. The practical value of the new model is particularly evident for meta-analyses in which only a few covariates are consistently measured across studies and hence there exist residual dependence. The covariate effects are formulated through the Cox proportional hazards model, and the baseline hazards are nonparametrically modeled on a basis of splines. The estimator is then obtained by maximizing a penalized log-likelihood function. We also show that the present methodologies are easily modified for the competing risks or recurrent event data, and are generalized to accommodate left-truncation. Simulations are performed to examine the performance of the proposed estimator. The method is applied to a meta-analysis for assessing a recently suggested biomarker CXCL12 for survival in ovarian cancer patients. We implement our proposed methods in R joint.Cox package.

Keywords

Dependent censoring dynamic prediction semicompeting risk spline surrogate endpoint survival analysis

Get full access to this article

View all access options for this article.

References

Pazdur

. Endpoints for assessing drug activity in clinical trials. Oncologist 2008; 13: 19–21.

Shi

Sargent

. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol 2009; 14: 102–111.

Michiels

Le Maître

Buyse

et al.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol 2009; 10: 341–350.

Buyse

Sargent

Saad

. Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol 2011; 29: 4719–4720.

Sherrill

Amonker

et al.

Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008; 99: 1542–1548.

Rondeau

Pignon

Michiels

. A joint model for dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer. Stat Meth Med Res 2015; 24: 711–729.

Cheema

Burkes

. Overall survival should be the primary endpoint in clinical trials for advanced non-small cell lung cancer. Curr Oncol 2013; 20: e150–e160.

Cox

. Regression models and life-tables (with discussion). J Royal Stat Soc Ser B 1972; 34: 187–220.

Burzykowski

Molenberghs

Buyse

. The Evaluation of Surrogate Endpoints, New York: Springer, 2005.

10.

Emura

Chen

. Gene selection for survival data under dependent censoring, a copula-based approach. Stat Meth Med Res 2016; 25: 2840–2857.

11.

Hougaard

. Analysis of Multivariate Survival Data, New York: Springer, 2000.

12.

Duchateau

Janssen

. The Frailty Model, New York: Springer, 2008.

13.

Crowder

. Multivariate Survival Analysis and Competing Risks, Boca Raton: CRC Press, 2012.

14.

Borenstein

Hedges

Higgins

JPT

et al.

Introduction to Meta-analysis, Wiley, 2009.

15.

Burzykowski

Molenberghs

Buyse

et al.

Validation of surrogate end points in multiple randomized clinical trials with failure time end points. Appl Stat 2001; 50: 405–422.

16.

Fine

Jiang

Chappell

. On semi-competing risks data. Biometrika 2001; 88: 907–920.

17.

Emura

. R joint.Cox: Penalized likelihood estimation under the joint Cox models between TTP and OS for meta-analysis. CRAN, R package version 2.0: 2015-06-18. CRAN: The Comprehensive R Archive Network.

18.

Popple

Durrant

Spendlove

et al.

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer 2012; 106: 1306–1313.

19.

Ganzfried

Riester

Haibe-Kains

et al.

Curated ovarian data: clinically annotated data for the ovarian cancer transcriptome. Database 2013. Article ID bat013, DOI: 10.1093/database/bat013.

20.

Tsiatis

. A nonidentifiability aspect of the problem of competing risks. Proc Natl Acad Sci USA 1975; 72: 20–22.

21.

Kryczek

Wei

Keller

et al.

Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol-Cell Physiol 2007; 292: C987–C995.

22.

Rondeau

Gonzalez

Mazroui

et al.

R frailtypack: general frailty models: shared, joint and nested frailty models with prediction

. CRAN, R package version 2.7.5: 2015-03-06. CRAN: The Comprehensive R Archive Network.

23.

Geerdens

Claeskens

Janssen

. Goodness-of-fit tests for the frailty distribution in proportional hazards models with shared frailty. Biostatistics 2013; 14: 433–446.

24.

Rondeau

Mathoulin-Pelissier

Jacqmin-Gadda

et al.

Joint frailty models for recurring events and death using maximum penalized likelihood estimation: Application on cancer events. Biostatistics 2007; 8: 708–721.

25.

Nelsen

. An introduction to Copulas, 2nd ed. New York: Springer Series in Statistics, Springer-Verlag, 2006.

26.

O' Sullivan

. Fast computation of fully automated log-density and log-hazard estimation. SIAM J Sci Stat Comput 1988; 9: 363–379.

27.

Joly

Commenges

Letenneur

. A penalized likelihood approach for arbitrary censored and truncated data: application to age-specific incidence of dementia. Biometrics 1998; 54: 185–194.

28.

Rondeau

Commenges

Joly

. Maximum penalized likelihood estimation in a gamma-frailty model. Lifetime Data Analysis 2003; 9: 139–153.

29.

Ramsay

. Monotone regression spline in action. Statis Sci 1988; 3: 425–461.

30.

Sabatier

Finetti

Adelaide

et al.

Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One 2011; 6: e27656.

31.

Jenssen

Kuo

Stokke

et al.

Association between gene expressions in breast cancer and patient survival. Human Genetics 2002; 111: 411–420.

32.

Matsui

. Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays. BMC Bioinformatics 2006; 7: 156.

33.

Emura

Chen

. Survival prediction based on compound covariate under Cox proportional hazard models. PLoS ONE 2012; 7: e47627.

34.

Clayton

. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 1978; 65: 141–151.

35.

Mauguen

Rachet

Mathoulin-Pélissier

et al.

Dynamic prediction of risk of death using history of cancer recurrences in joint frailty models. Stat Med 2013; 32: 5366–5380.

36.

Mauguen

Rachet

Mathoulin-Pélissier

et al.

Validation of death prediction after breast cancer relapses using joint models. BMC Med Res Methodol 2015; 15: 27.

37.

Chen

. Maximum likelihood analysis of semicompeting risks data with semiparametric regression models. Lifetime Data Anal 2012; 18: 36–57.

38.

Hsieh

Wang

Ding

. Regression analysis based on semicompeting risks data. J Royal Stat Soc: Ser B (Statistical Methodology) 2008; 70: 3–20.

39.

Rivest

Wells

. A martingale approach to the copula-graphic estimator for the survival function under dependent censoring. J Mult Anal 2001; 79: 138–155.

40.

Braekers

Veraverbeke

. A copula-graphic estimator for the conditional survival function under dependent censoring. Can J Stat 2005; 33: 429–447.

41.

Huang

Zhang

. Regression survival analysis with an assumed copula for dependent censoring. Biometrics 2008; 64: 1090–1099.

42.

Chen

. Semiparametric marginal regression analysis for dependent competing risks under an assumed copula. J Royal Stat Soc Ser B 2010; 72: 235–251.

43.

Stapline

Kimber

Collett

et al.

Dependent censoring in piecewise exponential survival models. Stat Meth Med Res 2015; 24: 325–341.

44.

Escarela

Carriere

. Fitting competing risks with an assumed copula. Stat Meth Med Res 2003; 12: 333–349.

45.

Fine

Gray

. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 548–560.

46.

Bakoyannis

Touloumi

. Practical methods for competing risks data: a review. Stat Meth Med Res 2012; 21: 257–272.

47.

Binder

Allignol

Schumacher

et al.

Boosting for high-dimensional time-to-event data with competing risks. Bioinformatics 2009; 25: 890–896.

48.

Do Ha

Christian

Jeong

et al.

Analysis of clustered competing risks data using subdistribution hazard models with multivariate frailties. Stat Meth Med Res 2016; 25: 2488–2505.

49.

González

Fernandez

Moreno

et al.

Sex differences in hospital readmission among colorectal cancer patients. J Epidemiol Commun Health 2005; 59: 506–511.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.09 MB